Pre-clinical Investigation Laboratory (LIP)
Strengthen efficacy and safety evidence using relevant preclinical models and translational data.
Offer overview
What this offer helps you achieve
Strengthen efficacy and safety evidence using relevant preclinical models and translational data.
Scientific and technical scope
LIP has developed a unique collection of 500 PDXs of different cancers (breast, lung, ovarian and prostate cancers; chordoma; uveal melanoma). All models are extensively characterised at the molecular level and in terms of drug response. We have also developed PDX, and organoids derived from patients with treatment-resistant breast and ovarian cancers. We bring our skills and knowledge to guide your projects, conducting extensive testing your products using our fully characterised models.
Capabilities mobilised
Therapeutic areasExpert adviceTherapeutic target discoveryValidation using preclinical modelsBiotestingPlatforms
Application fields
OncologyOphthalmologyRespiratory distress
Discuss this offer
Could this capability strengthen your R&D programme?
Present your scientific, technical or clinical need and identify the most relevant route to collaboration.
Find an offer